This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
between 18 and 65
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The purpose of this study is to evaluate the effect of lanabecestat on rosuvastatin. The amount of rosuvastatin in the blood will be compared, when taken alone, and then when taken with lanabecestat. The amount of lanabecestat that gets into the bloodstream will be measured. Information about any side effects that may occur will also be collected. Participants will be on study for 21 days with a follow-up at least 7 days afterwards. Screening will be undertaken within 45 days prior to enrollment.

Provided treatments

  • Drug: Lanabecestat
  • Drug: Rosuvastatin

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03019549. The sponsor of the trial is AstraZeneca and it is looking for 42 volunteers for the current phase.
Official trial title:
Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects